SG152265A1 - Aerosol formulation for inhalation of beta agonists - Google Patents

Aerosol formulation for inhalation of beta agonists

Info

Publication number
SG152265A1
SG152265A1 SG200902777-2A SG2009027772A SG152265A1 SG 152265 A1 SG152265 A1 SG 152265A1 SG 2009027772 A SG2009027772 A SG 2009027772A SG 152265 A1 SG152265 A1 SG 152265A1
Authority
SG
Singapore
Prior art keywords
inhalation
aerosol formulation
beta agonists
agonists
beta
Prior art date
Application number
SG200902777-2A
Other languages
English (en)
Inventor
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG152265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG152265A1 publication Critical patent/SG152265A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG200902777-2A 2004-05-14 2005-05-10 Aerosol formulation for inhalation of beta agonists SG152265A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004024452A DE102004024452A1 (de) 2004-05-14 2004-05-14 Aerosolformulierung für die Inhalation von Betaagonisten

Publications (1)

Publication Number Publication Date
SG152265A1 true SG152265A1 (en) 2009-05-29

Family

ID=34979667

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902777-2A SG152265A1 (en) 2004-05-14 2005-05-10 Aerosol formulation for inhalation of beta agonists

Country Status (26)

Country Link
EP (1) EP1809293B1 (pt)
JP (1) JP4620730B2 (pt)
KR (1) KR101288791B1 (pt)
CN (1) CN101056640A (pt)
AR (1) AR049096A1 (pt)
AU (1) AU2005244414B2 (pt)
BR (1) BRPI0511135B8 (pt)
CA (1) CA2564379C (pt)
DE (1) DE102004024452A1 (pt)
DK (1) DK1809293T3 (pt)
EA (1) EA012583B1 (pt)
EC (1) ECSP067004A (pt)
ES (1) ES2575925T3 (pt)
HU (1) HUE027780T2 (pt)
IL (1) IL179218A (pt)
MX (1) MXPA06013216A (pt)
MY (1) MY148403A (pt)
NO (1) NO20065030L (pt)
PE (1) PE20060311A1 (pt)
PL (1) PL1809293T3 (pt)
SG (1) SG152265A1 (pt)
TW (1) TWI356703B (pt)
UA (1) UA87312C2 (pt)
UY (1) UY28891A1 (pt)
WO (1) WO2005110421A2 (pt)
ZA (1) ZA200607462B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
JP5270343B2 (ja) 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータミメティックスの製造方法
WO2007054498A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
EP2358350A1 (en) * 2008-11-21 2011-08-24 Boehringer Ingelheim International GmbH Aerosol formulation for the inhalation of beta agonists
WO2010057927A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPH0637388B2 (ja) * 1986-02-17 1994-05-18 千寿製薬株式会社 水性液剤
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
SI2422786T1 (sl) * 2004-04-22 2014-12-31 Boehringer Ingelheim International Gmbh Nove farmacevtske kombinacije za zdravljenje respiratornih obolenj
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten

Also Published As

Publication number Publication date
UA87312C2 (ru) 2009-07-10
EP1809293B1 (de) 2016-03-16
ECSP067004A (es) 2007-02-28
MXPA06013216A (es) 2007-02-08
ZA200607462B (en) 2008-06-25
KR101288791B1 (ko) 2013-07-29
HUE027780T2 (en) 2016-11-28
EP1809293A2 (de) 2007-07-25
BRPI0511135B1 (pt) 2019-11-12
DK1809293T3 (en) 2016-06-20
AU2005244414A1 (en) 2005-11-24
BRPI0511135A (pt) 2007-11-27
AR049096A1 (es) 2006-06-28
TWI356703B (en) 2012-01-21
KR20070022084A (ko) 2007-02-23
CA2564379A1 (en) 2005-11-24
EA012583B1 (ru) 2009-10-30
ES2575925T3 (es) 2016-07-04
IL179218A0 (en) 2007-03-08
TW200608981A (en) 2006-03-16
CA2564379C (en) 2013-07-30
EA200602017A1 (ru) 2007-06-29
AU2005244414B2 (en) 2010-12-09
NO20065030L (no) 2006-11-30
JP4620730B2 (ja) 2011-01-26
JP2007537188A (ja) 2007-12-20
BRPI0511135B8 (pt) 2021-05-25
WO2005110421A3 (de) 2006-03-16
DE102004024452A1 (de) 2005-12-08
WO2005110421A2 (de) 2005-11-24
UY28891A1 (es) 2005-12-30
PL1809293T3 (pl) 2016-09-30
MY148403A (en) 2013-04-30
CN101056640A (zh) 2007-10-17
PE20060311A1 (es) 2006-05-08
IL179218A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
HRP20180713T1 (hr) Aerosolna formulacija za inhaliranje beta-agonista
IL197024A0 (en) Aerosol formulation for the inhalation of beta agonists
IL197025A0 (en) Aerosol formulation for the inhalation of beta agonists
IL179218A0 (en) Aerosol formulation for inhalation of beta agonists
IL191809A0 (en) Powder compositions for inhalation
IL174496A0 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
EP1993646A4 (en) CONFIGURATION OF NOZZLE PORES FOR INTRA-PULMONARY ADMINISTRATION OF AEROSOL FORMULATIONS
DK1809236T3 (da) Pulverformuleringer til inhalation indeholdende enatiomeriske rene beta-agonister
EP1806148A4 (en) THERAPEUTIC PREPARATION FOR INHALATION
ZA200903840B (en) Powder formulation for valganciclovir
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
ZA200806929B (en) Nebulizer formulation
GB0416328D0 (en) Use of dry powder compositions for pulmonary delivery
ZA200704977B (en) Nebulizer formulation
PT1496876E (pt) Formulação de aerossol para a inalação contendo brometo de tiotrópio
ZA200900370B (en) Aerosol formulation for the inhalation of beta agonists
ATE401861T1 (de) Tiotropiumhaltige pulverformulierung für die inhalation
EP2086943A4 (en) NEW COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF APPLICATION
PL2167042T3 (pl) Kompozycje farmaceutyczne w aerozolu zawierające flutykazon
EP1931327A4 (en) CYCLOPROPYL COMPOUNDS AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES
ZA200900418B (en) Aerosol formulation for the inhalation of beta agonists
AP2006003734A0 (en) Inhalation formulation
ZA200606181B (en) Aerosol formulation
GB0519083D0 (en) Compositions for the improved delivery of medicaments
PL371710A1 (pl) Środek do zwalczania zagrożeń pyłowych